AUTHORS
Bhagirathbhai Dholaria, MD, FACP, Caspian Oliai, MD2, Siddhartha Reddy, MD3, Nelli Bejanyan, MD4, Alexandra Gomez-Arteaga, MD5, Anna Pavlova, MD, PhD6, Renata Gilfanova, MD7, J. Scott McClellan, MD, PhD8, Nate B. Fernhoff, PhD9, Arpita Gandhi, M.D., M.S.10
AFFILIATIONS
1 Vanderbilt University Medical Center, Nashville, United States
2 UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
3 Hackensack University Medical Center, Hackensack, New Jersey, United States
4 Moffitt Cancer Center, Tampa, Florida, United States
5 Weill Cornell Medicine, New York, New York, United States
6 Orca Bio, Menlo Park, California, United States
7 Orca Bio, Menlo Park, California, United States
8 Orca Bio, Menlo Park, California, United States
9 Orca Bio, Menlo Park, California, United States
10 Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, United States
ABSTRACT
Background: Reduced-intensity conditioning (RIC) and nonmyeloablative (NMA) conditioning expands access to alloHSCT for patients who are older or more frail, who would otherwise not tolerate myeloablative conditioning (MAC). There is a high unmet need to improve post-transplant outcomes in this already vulnerable population. Allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq (Orca-T) is a precision-engineered allogeneic stem cell and T-cell immunotherapy for alloHSCT, that leverages highly purified, regulatory T cells to control alloreactive immune responses. Orca-T has been investigated in the randomized phase 3 Precision-T trial in the MAC setting, and this study seeks to define a preliminary safety and efficacy profile in the RIC and NMA setting.
Study Design and Methods: SERENE-T (NCT07216443) is a Phase 2 multicenter, open label study of Orca-T following Investigator choice of either RIC or NMA, in either outpatient or inpatient setting. Eligible participants (age ≥18) include AML in CR/CRi or MDS (<10% blasts) and with an 8/8 HLA-matched related or unrelated donor. Participants in the RIC cohort will receive TBI 200 or 400 cGy, thiotepa 5mg/kg and fludarabine 160 mg/m2 conditioning. Participants in the NMA cohort will receive fludarabine 120mg/m2 or 150mg/m2, cyclophosphamide 50mg/kg and TBI 200 cGY conditioning. In both cohorts GVHD prophylaxis is single-agent tacrolimus beginning the day following T con infusion (typically day +3). The primary endpoint is GVHD-free and relapse‑free survival (GRFS; Holtan, 2015) through day 365 in the RIC cohort. The primary endpoint in the NMA cohort is incidence and timing of neutrophil engraftment through day +28. Secondary endpoints across both cohorts include, incidence of graft failure, incidence of acute graft-versus-host disease (aGVHD) and chronic GVHD (cGVHD), nonrelapse mortality (NRM), incidence and severity of grade ≥3 infections, overall survival (OS), relapse free survival (RFS), GRFS and survival free from moderate-to-severe chronic GVHD (cGFS).
Conclusions: The SERENE-T study is currently enrolling participants across multiple sites in the United States, with an anticipated total enrollment of 80 participants. The trial is designed to further characterize the safety and tolerability of Orca-T and to evaluate preliminary efficacy of Orca-T in participants eligible for RIC-alloHSCT or NMA-alloHSCT.
DISCLOSURES
Bhagirathbhai Dholaria, MD, FACP: MJH BioScience, Arivan Research, Janssen, ADC Therapeutics, Gilead, GSK, Caribou, Roche, Autolus, Poseida, and AstraZeneca - Honoraria; merck - Research Funding; Janssen - Research Funding; MJH BioScience, Arivan Research, Janssen, ADC Therapeutics, Gilead, GSK, Caribou, Roche, Autolus, Poseida, and AstraZeneca - Consultancy (Includes expert testimony)